Pulmonary arterial hypertension (PAH) is no longer an orphan disease. There are three
different classes of drugs for the treatment of PAH that are currently being used and an …

The prognosis of most leukemia patients treated with BCR‐ABL tyrosine kinase inhibitors
(TKIs) is favorable, and a more precise understanding of serious and potentially irreversible …

Background—The French pulmonary hypertension (PH) registry allows the survey of
epidemiological trends. Isolated cases of precapillary PH have been reported in patients …

Objective—Pulmonary arterial hypertension is a progressive pulmonary vascular disorder
with high morbidity and mortality. Compelling evidence suggests that receptor tyrosine …

In patients with chronic myeloid leukemia (CML), use of the BCR–ABL1-specific tyrosine
kinase inhibitors (TKIs) imatinib, nilotinib and dasatinib has greatly improved patient survival …

Chronic myeloid leukemia (CML), a myeloproliferative disorder caused by the over activity of
BCR-ABL1 (breakpoint cluster region-Abelson), has been successfully treated by Tyrosine …

Tyrosine kinase inhibitors (TKIs) have potent effects on malignant cells, and they also target
kinases in normal cells, which may have therapeutic implications. Using a collection of 55 …

Drug‐induced (group 1) pulmonary hypertension (PH) is an important subgroup of PH
involving dasatinib as a likely related agent, which is a second‐generation tyrosine kinase …

The diagnosis of pulmonary arterial hypertension (PAH) is frequently delayed. We
hypothesized that circulating angiogenic modulatory protein levels might correspond with …

Purpose Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI) designed as a prototypic
short-acting BCR–ABL-targeted TKI that inhibits BCR–ABL with greater potency compared …